MHC-binding peptides as immunotherapeutics for cancer

Immunol Invest. 2000 May;29(2):105-10. doi: 10.3109/08820130009062291.

Authors

H Kobayashi¹, R Kennedy, J Lu, E Davila, E Celis

Affiliation

¹ Department of Immunology and Mayo Graduate School, Mayo Clinic, Rochester, MN 55905, USA.

PMID: 10854176
DOI: 10.3109/08820130009062291

No abstract available

MeSH terms

Antigens, Neoplasm / metabolism*
Carcinoembryonic Antigen / immunology
Cytotoxicity, Immunologic
Epitopes / metabolism
Histocompatibility Antigens Class I / metabolism*
Histocompatibility Antigens Class II / metabolism*
Humans
Immunotherapy / methods*
In Vitro Techniques
Neoplasm Proteins / immunology
Neoplasms / immunology
Neoplasms / therapy*
Peptides / immunology*
Peptides / metabolism*
Protein Binding
Receptor, ErbB-2 / immunology
T-Lymphocytes, Cytotoxic / immunology

Substances

Antigens, Neoplasm
Carcinoembryonic Antigen
Epitopes
Histocompatibility Antigens Class I
Histocompatibility Antigens Class II
MAGEB2 protein, human
Neoplasm Proteins
Peptides
Receptor, ErbB-2